Upperton Pharma Solutions Named One of The Sunday Times Best Places to Work 2025
Upperton Pharma Solutions Named One of The Sunday Times Best Places to Work 2025.
The Sunday Times Best Places to Work Awards, powered by WorkL, evaluate organisations based on comprehensive employee surveys. These surveys assess key engagement drivers, including Reward & Recognition, Information Sharing, Empowerment, Pride, Job Satisfaction, and Wellbeing. To qualify, companies must achieve a minimum overall engagement score of 70%. Being named in the list signals that an organisation not only meets these benchmarks but also demonstrates a consistent commitment to building a workplace culture that enables people to perform and grow.
Nikki Whitfield, CEO of Upperton Pharma Solutions, expressed her pride in the achievement:
“Being recognised as one of The Sunday Times Best Places to Work is a testament to our commitment to our employees. We invest in creating a working culture that supports both technical excellence and professional growth, and it’s encouraging to see those efforts reflected in this result”.
Upperton’s inclusion in the 2025 list follows a year of significant milestones, including expansion into sterile manufacturing and investment in talent across scientific and operational teams. The company’s culture, emphasising collaboration, innovation, and employee empowerment, has been instrumental in driving its growth and success.
Nicola Beer, HR Manager at Upperton, added:
“This recognition underscores our focus on fostering a culture where every employee feels valued and heard. We continuously strive to implement initiatives that promote wellbeing, professional growth, and innovation within our organisation.”
Upperton Pharma Solutions specialises in formulation development, clinical trial manufacturing, and commercial manufacturing across various dosage forms, including oral solids, liquids, semi-solids, inhalation and sterile products. With a state-of-the-art 60,000 sq ft facility in Nottingham, the company offers integrated CDMO services from pre-clinical development through to market supply.
About Upperton Pharma Solutions:
Upperton has over 25 years’ experience of delivering science-led, high quality, innovative drug development and manufacturing solutions to pharmaceutical and biotechnology clients worldwide.
Based in Nottingham, UK, Upperton has a 60,000 sq. ft development and manufacturing facility, with formulation and analytical development laboratories, alongside a fully equipped GMP manufacturing and quality control testing capability. Upperton is MHRA Approved to manufacture materials for clinical trial supplies. In addition to supporting conventional oral solid dosage form development, Upperton has a strong history in spray drying which addresses both the challenges with poorly soluble molecules and as a particle engineering technology for targeted deposition for pulmonary and nasal drug products.
The company employs around one hundred highly skilled personnel and has its headquarters in Nottingham, UK.
For further information, images, and interview opportunities, please contact:
Rob Halliwell, Associate Director of Marketing, Upperton
rob.halliwell@upperton.com
upperton.com
